Navigation Links
Deep Brain Stimulation Works in Two Sites for Parkinson's Disease
Date:6/2/2010

Choice of area to pinpoint can be tailored to individual patients, researchers say ,,

WEDNESDAY, June 2 (HealthDay News) -- People suffering from Parkinson's disease can benefit from deep brain stimulation in either one of two sites in the brain, a new study finds.

The Veterans Affairs researchers compared two different targets in the brain for deep brain stimulation -- the subthalamic nucleus (STN) and the globus pallidus interna (GPi) -- both of which affect motor function. The procedure involves placing a fine wire into either of the two areas, after which an implanted battery delivers a finely tuned electrical current to stimulate the brain, often resulting in dramatic improvement in motor function.

"Most of the neurosurgery field has been using the STN target, with little strong evidence that it was the best target for stimulation," said researcher Frances Weaver, director of the Center for Management of Complex Chronic Care at Hines VA Hospital in Illinois.

"But recent reports suggest that there may be some negative consequences of STN targeting, including cognitive and psychological changes," she added.

The report is published in the June 3 issue of the New England Journal of Medicine.

For this study, researchers compared the STN and GPi targets in a randomized trial and looked at patient outcomes. In the trial, 299 patients were assigned to either STN or GPi deep brain stimulation.

Weaver's team found that patients improved equally in motor function, regardless of which target was used.

Overall, about half of the patients had serious side effects. The most common was infection at the incision site. By the end of the two-year study, 99 percent of these side effects were resolved.

"The decision as to which target in the brain to stimulate to treat Parkinson's disease should consider the other symptoms and problems of Parkinson's disease," Weaver said. For example, the use of medications can be reduced to a greater extent after STN stimulation than GPi stimulation, she noted.

"Medication has effects on other symptoms, so if a patient is experiencing other symptoms besides motor problems that are better managed by medication, you may want to select the GPi -- where less reduction in medication is necessary," Weaver said.

Both STN and GPi deep brain stimulation are equally effective in improving motor symptoms in people with advanced Parkinson's disease, Weaver said.

"Serious adverse events are frequent for both targets, but are resolved through stimulation or medication adjustments, and other interventions, as needed," she added.

Dr. Michael Okun, national medical director of the National Parkinson Foundation, said that "this is an important study for Parkinson's disease patients and for their doctors as it opens the door for tailoring therapy and for tailoring brain targets for individual symptom profiles."

He added: "This two-year prospective randomized study showed that both STN and GPi were effective in treating the motor symptoms of Parkinson's disease, and that there were subtle but potentially important differences between targets."

The first signs of Parkinson's are usually motor control problems such as shaking, rigidity, slowed movement and poor balance. In later stages, patients develop a variety of cognitive and mood problems, including depression, apathy, slowed thinking, confusion, impaired memory and trouble sleeping.

In early stages of the disease, motor symptoms can be controlled by medications such as L-dopa. But for patients with advanced Parkinson's, the drugs are less effective.

More information

For more information on Parkinson's disease, visit the National Parkinson Foundation.



SOURCES: Frances Weaver, Ph.D., director, Center for Management of Complex Chronic Care, Hines VA Hospital, Hines, Ill.; Michael Okun, M.D., national medical director, National Parkinson Foundation; June 3, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New Hope for Brain, Spinal Cord Injuries
2. UPMC Health Plan Offers Brain Fitness Software to Improve Health
3. NFL Brain Injury Panel Raises Awareness of Potential Long-Term Consequences from Traumatic Brain Injuries
4. Melatonin precursor stimulates growth factor circuits in brain
5. Brain Scans Suggest Some Vegetative Patients May Be Aware
6. Brain Damage Seen in People With Severe Sleep Apnea
7. Alterations in the brains reward system related to attention-deficit/hyperactivity disorder
8. Brain dopamine receptor density correlates with social status
9. 3 brain diseases linked by toxic form of same neural protein
10. Brain Damage: NFL ‘Gets It,' American Society of Anesthesiologists Still Appears ‘Asleep'
11. Study finds reduced brain gray matter concentration in patients with severe obstructive sleep apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. , ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical ... ("Precision Lens"), today announced the signing of a ... Precision Lens will deploy a dedicated sales team ... in the U.S., primarily focused in 13 states ...
Breaking Medicine Technology: